Full-Time
Area Sales Director
Updated on 9/17/2026
Tenpoint Therapeutics
51-200 employees
Engineered cell therapies to restore vision
Compensation Overview
$200k - $240k/yr
Remote in USA
Remote
Remote within the United States, with travel to client sites required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Tenpoint Therapeutics
See people who can refer or advise you
- At least 6 years of documented sales success is required.
- At least 2 years of people leadership experience leading consistently top-performing teams.
- A bachelor's degree or equivalent experience is required.
- An unexpired driver's license and satisfactory driving record are required.
- The ability to travel to client sites by car, plane, train, taxi, or other transportation is required.
- The ability to operate a computer and communicate effectively in a remote work environment is required.
- The ability to sit for extended periods, participate in video or phone meetings, and use standard office equipment is required.
- The ability to occasionally lift and transport materials up to 25 pounds is required.
- Attract, hire, onboard, and retain Specialty Sales Managers while creating a people-first, performance-driven culture with clear standards and accountability.
- Design territory and account plans, coverage models, call cadence, routing, and goals; guide resource deployment and launch activities with eye-care professional practices.
- Conduct regular field rides and one-on-one meetings, diagnose representative strengths and gaps, provide actionable feedback and development plans, and model compliant, evidence-based selling.
- Deliver commitments and lead the team to meet and exceed sales targets and activity metrics.
- Ensure teams lead with clinical evidence, patient selection, onset and duration expectations, safety, and workflow enablement to drive consistent practice behaviors.
- Equip the sales team and practices to drive adoption of an out-of-pocket therapy and oversee patient education and appropriate starter resources.
- Collaborate with Sales Training, Marketing, Operations, and other internal partners to prioritize needs across key business areas.
- Navigate ambiguity, adapt quickly, and guide the team through launch phases, expansions, and process improvements while maintaining integrity and compliance.
- Pharmaceutical, medical, or closely related sales experience.
- Eye-care or contact lens sales experience.
- Pharmaceutical launch experience.
- Start-up experience.
TenPoint Therapeutics develops regenerative therapies for eye diseases. Its main approach is engineered cell-based therapeutics and in vivo reprogramming to replace damaged retinal or ocular tissue and potentially restore vision with a single, long-lasting treatment. Unlike many groups that work on generic regenerative methods, TenPoint focuses on the eye’s unique environment to direct therapies and reverse disease progression. The company aims to bring these regenerative solutions to patients by partnering with healthcare providers, with the ultimate goal of restoring sight and improving quality of life. The founding team comes from leading ocular research centers, giving them deep expertise in regenerative biology and translational medicine.
Company Size
51-200
Company Stage
Debt Financing
Total Funding
$305M
Headquarters
London, United Kingdom
Founded
2020
Get referred to Tenpoint Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Tenpoint raised $235 million on January 28, 2026, funding launch and expansion.
- March 30, 2026 U.S. availability plus PHIL cash access removes pharmacy friction for patients.
- Stephen S. Lane joined April 7, 2026, strengthening ophthalmology credibility and medical affairs execution.
What critics are saying
- YUVEZZI carries retinal detachment, vascular insufficiency, and low-light driving warnings in labeling.
- LENZ VIZZ, AbbVie Vuity, and Orasis Qlosi crowd presbyopia before Tenpoint gains share.
- If U.S. prescriptions stay weak, Tenpoint's 2026 launch burns $235 million without diversification.
What makes Tenpoint Therapeutics unique
- YUVEZZI won FDA approval on January 28, 2026, as the first dual-agent presbyopia drop.
- It pairs carbachol and brimonidine for once-daily, up-to-10-hour near-vision improvement.
- August 21, 2026 Lupin deal extends YUVEZZI into Europe, the UK, Switzerland, Norway, and Iceland.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Paid Vacation
Paid Holidays
Paid Sick Leave
401(k) Retirement Plan
401(k) Company Match
Hybrid Work Options
Wellness Program
Stock Options
Company News
Lupin arm to commercialise YUVEZZI eye drop across key European markets. PTI Last Updated: Aug 20, 2026, 01:14:00 PM IST Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia. New Delhi: Pharma major Lupin Ltd on Thursday said its wholly-owned arm VISUfarma BV has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise YUVEZZI, an ophthalmic product indicated for the treatment of loss of clear close-up vision in adults, in specified global markets. The licensing pact with Visus Therapeutics Inc, a wholly-owned arm of Tenpoint Therapeutics Holding Ltd, provides VISUfarma exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, in the European Union, the UK, Switzerland, Norway and Iceland, Lupin said in a regulatory filing. You May Like Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales, it added. The total potential consideration under the agreement is up to 75 million euros through to first commercial sales in the territory, the company said. It comprises a 20 million euro strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument, which provides the right to receive capital stock of Visus or its parent entity upon the occurrence of specified equity financing or public listing events, and up to 55 million euro in regulatory and commercial milestone payments, the filing added. In addition, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the Licensed Territories, in accordance with the terms of the agreement, it added. "Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets," Lupin CEO Vinita Gupta said. She further said, "The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the licensed territories." Tenpoint CEO Henric Bjarke said, "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's long-standing presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI to Europe." The company said that, as the first and only approved once-daily, dual-agent eye drop for presbyopia, YUVEZZI represents a significant advancement in eye care. Presbyopia is a condition when eyes gradually lose the ability to see things clearly up close.
Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.
Tenpoint Therapeutics has launched a national consumer campaign for YUVEZZI, the first FDA-approved dual-agent, once-daily prescription eye drop for treating presbyopia. The condition affects approximately 128 million adults in the US and two billion people globally. The "Friends of the Presbyopians" campaign features hand-crafted puppets representing everyday objects like restaurant menus, smartphones and reading glasses. The puppets humorously voice frustrations about being overused as workarounds for blurry close-up vision, highlighting the daily adjustments people with presbyopia make. YUVEZZI combines carbachol and brimonidine tartrate to improve near vision. Clinical studies showed it provided up to eight continuous hours of improved close-up vision, with some patients reading three more lines on an eye chart within 30 minutes. The campaign launches nationwide across digital and social channels.
Ritedose announces manufacturing for Tenpoint Therapeutics' presbyopia eye drop. GlobeNewswire | The Ritedose Corporation Today at 5:34am PDT COLUMBIA, S.C., April 08, 2026 (GLOBE NEWSWIRE) - The Ritedose Corporation, Inc. (Ritedose), the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is partnering with Tenpoint Therapeutics, Ltd. to manufacture YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia. The selection of Ritedose as a CDMO reflects a deliberate commitment to commercial readiness and supply security. In the ophthalmic space, where validated sterile manufacturing and rigorous quality oversight are critical to earning the confidence of investors, physicians, and the broader market, partnering with a proven manufacturer is a strategic imperative. By aligning with Ritedose and its more than 25 years of experience in sterile ophthalmic and respiratory manufacturing, Tenpoint has meaningfully de-risked its production pathway and demonstrated the discipline to choose best-in-class partners in bringing YUVEZZI to patients at scale. "Our leading aseptic manufacturing capabilities make Ritedose the ideal partner to deliver safe and effective doses of YUVEZZI to patients," said Jody Chastain, president and CEO of Ritedose. "We have been serving the ophthalmic and the respiratory markets for over 25 years, and this partnership reflects what that track record means in practice. Tenpoint Therapeutics chose us - a CDMO with proven execution, supply chain security and an uncompromised standard of quality. We are proud to help Tenpoint Therapeutics bring this treatment to the patients who need it." "Ritedose is proud to work alongside Tenpoint Therapeutics on the manufacturing of national launch quantities of YUVEZZI so this treatment can be available to all presbyopia patients who need it," continued Chastain. About The Ritedose Corporation Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company's process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com. About Tenpoint Therapeutics Tenpoint Therapeutics Ltd. is a commercial-stage ophthalmic pharmaceuticals company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the US and approximately two billion people globally. By understanding real-world needs and partnering with care eye professionals, Tenpoint is working to bring innovation to the aging eye. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn. Media Contacts Alex Keown Inspire Agency on behalf of Ritedose [email protected] 630-346-5141 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.
Tenpoint Therapeutics appoints Stephen S. Lane, MD, as Chief Medical Officer. Ophthalmology luminary and former Alcon CMO joins Tenpoint Therapeutics April 7, 2026 Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment of Stephen S. Lane, MD, as Chief Medical Officer (CMO). In this role, Dr. Lane will join the executive team and oversee the company's clinical development strategy, medical affairs and pharmacovigilance. Dr. Lane brings significant ophthalmology leadership experience in clinical practice and the pharmaceutical industry, most recently serving as CMO and Head of Medical Safety at Alcon, Inc. He is recognized as a world-renowned ophthalmologist with more than 40 years of experience. Dr. Lane is the past President of the American Society of Cataract and Refractive Surgery (ASCRS), a former member of the Committee of Secretaries at the American Academy of Ophthalmology (AAO), a former Board Member and Officer of the International Society of Refractive Surgery (ISRS) and a Board Member of the Minnesota Academy of Ophthalmology. He has been honored with numerous awards, including the AAO Honor Award, Senior Achievement Award and Secretariat Award. "Dr. Lane is a highly respected ophthalmology leader whose experience spans clinical practice, product development and medical leadership at the highest levels of the industry," said Henric Bjarke, chief executive officer of Tenpoint Therapeutics. "He is exceptionally well suited to help drive Tenpoint Therapeutics as we advance innovative therapies for the aging eye and enter this next stage of commercial growth." Career highlights. Throughout his career, Dr. Lane has contributed extensively to clinical research and education, participating in more than 50 clinical trials, delivering over 400 lectures globally, presenting six domestic and international medical lectures and authoring numerous academic articles and book chapters. He also holds several biomedical patents. He currently serves as chief executive officer of the Holland Foundation for Sight Restoration, a nonprofit organization focused on establishing centers of excellence for ocular stem cell transplantation and advancing the education of corneal surgeons, and as a clinical professor of ophthalmology at the University of Minnesota. "I am excited to join Tenpoint Therapeutics at a time of significant opportunity for the Company and the field of ophthalmology," said Dr. Lane. "Tenpoint Therapeutics' dedication to advancing innovative treatments for the aging eye aligns closely with my passion for improving patient outcomes. I look forward to working with the team to further develop and deliver solutions that address the unmet needs of both patients and the eye care professionals who care for them." Dr. Lane earned his medical degree from the University of Minnesota, completed his ophthalmology residency at Pennsylvania State University and is fellowship-trained in cornea/external disease, anterior segment surgery and refractive surgery.